Heidelberg Pharma's proprietary ATAC technology

DGAP-News: Heidelberg Pharma Participates at Various Conferences

Retrieved on: 
Thursday, October 28, 2021
RNA transfection, Non-Hodgkin lymphoma, CFO, Cancer, Eukaryote, Control, ISIN, Survival, CD37, ATAC, RNA polymerase II, CET, II, Antibody, RNA, Frankfurt Stock Exchange, PSMA, CSO, Company, CEO, Antibody-drug conjugate, ATACS, BCMA, Multiple myeloma, Medical device, Fine chemical, Heidelberg Pharma's proprietary ATAC technology, Heidelberg Pharma, HEIDELBERG PHARMA'S PROPRIETARY ATAC TECHNOLOGY, HEIDELBERG PHARMA

Antibody Drug Conjugates (ADCs) combine the high affinity and specificity of antibodies with the potency of cytotoxic small molecules for the treatment of cancer.

Key Points: 
  • Antibody Drug Conjugates (ADCs) combine the high affinity and specificity of antibodies with the potency of cytotoxic small molecules for the treatment of cancer.
  • Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany.
  • Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies.
  • Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA.

DGAP-News: Heidelberg Pharma Announces Participation at Various Conferences

Retrieved on: 
Thursday, June 17, 2021
Baden, Ladenburg, Rhein-Neckar-Kreis, Geography of Germany, Heidelberg, Subdivisions of Germany, Heidelberg Pharma's proprietary ATAC technology, Heidelberg Pharma, HEIDELBERG PHARMA'S PROPRIETARY ATAC TECHNOLOGY, HEIDELBERG PHARMA

Ladenburg, Germany, 17 June 2021 - Heidelberg Pharma AG (FSE: HPHA) today announced that they will present its proprietary ATAC technology at two upcoming scientific events.

Key Points: 
  • Ladenburg, Germany, 17 June 2021 - Heidelberg Pharma AG (FSE: HPHA) today announced that they will present its proprietary ATAC technology at two upcoming scientific events.
  • Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany.
  • Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies.
  • Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA.

DGAP-News: Heidelberg Pharma to Present New Data on its Proprietary ATAC Technology Platform at the AACR Annual Meeting 2021

Retrieved on: 
Wednesday, March 31, 2021
Branches of biology, Glutamate carboxypeptidase II, Molecular neuroscience, Neurotransmitters, Peptidase, Biology, Prostate cancer, Heidelberg Pharma's proprietary ATAC technology, Heidelberg Pharma

Ladenburg, Germany, 31 March 2021 - Heidelberg Pharma AG (FSE: HPHA) announced today that it will present preclinical data on its novel ATAC candidates HDP-102 and HDP-103 as well as data on synergistic effects of ATACs with checkpoint inhibitors at the American Association for Cancer Research (AACR) 2021 Annual Meeting.

Key Points: 
  • Ladenburg, Germany, 31 March 2021 - Heidelberg Pharma AG (FSE: HPHA) announced today that it will present preclinical data on its novel ATAC candidates HDP-102 and HDP-103 as well as data on synergistic effects of ATACs with checkpoint inhibitors at the American Association for Cancer Research (AACR) 2021 Annual Meeting.
  • Details of the poster presentation - PSMA ATACs:
    The poster presentation will cover preclinical data on ATACs targeting PSMA (prostate-specific membrane antigen).
  • The proprietary technology platform is being applied to develop the Company's own therapeutic ATACs as well as in third-party collaborations.
  • Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0/ WKN A11QVV / Symbol HPHA.

DGAP-News: Heidelberg Pharma and Indiana University Publish Results on HER2-ATAC for Targeted Immunotherapy of Triple Negative Breast Cancer in Science Translational Medicine

Retrieved on: 
Thursday, February 11, 2021
Clinical medicine, Medicine, Medical specialties, Immunology, Cancer treatments, Trastuzumab emtansine, Trastuzumab, HER2/neu, Breast cancer, Pertuzumab, Heidelberg Pharma's proprietary ATAC technology, Heidelberg Pharma

HER2 is a surface protein that is overexpressed by breast cancer cells.

Key Points: 
  • HER2 is a surface protein that is overexpressed by breast cancer cells.
  • TNBC cells do express HER2, albeit at a low level (HER2-low) that is not sufficient for treatment with Trastuzumab antibody or Kadcyla.
  • Andreas Pahl, Chief Scientific Officer at Heidelberg Pharma, commented: "We are delighted with the publication of these extraordinary data in the Science Translational Medicine journal.
  • Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA.

DGAP-News: Heidelberg Pharma will Present at German Equity Forum and Provides Update on Partner Activities for its Legacy Assets

Retrieved on: 
Thursday, November 12, 2020
Baden, Ladenburg, Rhein-Neckar-Kreis, Heidelberg, Geography of Germany, Subdivisions of Germany, Heidelberg Pharma's proprietary ATAC technology, Heidelberg Pharma

Ladenburg, Germany, 12 November 2020 - Heidelberg Pharma AG (FSE: HPHA) today announced that it will give a presentation at the German Equity Forum (Eigenkapitalforum, EKF) and provided an update on recent news from its licensing partners.

Key Points: 
  • Ladenburg, Germany, 12 November 2020 - Heidelberg Pharma AG (FSE: HPHA) today announced that it will give a presentation at the German Equity Forum (Eigenkapitalforum, EKF) and provided an update on recent news from its licensing partners.
  • Dr. Jan Schmidt-Brand, CEO/CFO of Heidelberg Pharma AG will hold a company presentation on Wednesday, 18th November at 10:00 am CET.
  • Dr. Jan Schmidt-Brand said: "We are pleased that our partners are making significant progress with our out-licensed product candidates.
  • Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA.

DGAP-News: Heidelberg Pharma Announces Several Presentations of Research Results on ATAC Technology at the ASH Annual Meeting 2020

Retrieved on: 
Thursday, November 5, 2020
Branches of biology, Gene expression, Nucleic acids, Biology, Amatoxin, RNA polymerase II, Messenger RNA, RNA polymerase, Transcription, Polymerase, Amanitin, alpha-Amanitin, Heidelberg Pharma's proprietary ATAC technology, Heidelberg Pharma

Antibody Targeted Amanitin Conjugates (ATACs) are ADCs whose active ingredient is made up of amatoxin molecules.

Key Points: 
  • Antibody Targeted Amanitin Conjugates (ATACs) are ADCs whose active ingredient is made up of amatoxin molecules.
  • They inhibit mRNA transcription by binding to RNA polymerase II, a mechanism that is crucial for the survival of eukaryotic cells.
  • This proprietary technology platform is being applied to develop the Company's proprietary therapeutic ATACs, as well as in third-party collaborations, to create a variety of ATAC candidates.
  • Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA.

DGAP-News: Heidelberg Pharma Receives Milestone Payment from Partner Magenta

Retrieved on: 
Monday, September 14, 2020
MGTA, Magenta Therapeutics, Heidelberg Pharma's proprietary ATAC technology, Heidelberg Pharma

Ladenburg, Germany, 14 September 2020 - Heidelberg Pharma AG (FSE: HPHA) announced today that it has received a milestone payment from its cooperation partner Magenta Therapeutics, Cambridge, MA, USA, (Magenta) (NASDAQ: MGTA) associated with the initiation of the GLP toxicology study for the development candidate MGTA-117.

Key Points: 
  • Ladenburg, Germany, 14 September 2020 - Heidelberg Pharma AG (FSE: HPHA) announced today that it has received a milestone payment from its cooperation partner Magenta Therapeutics, Cambridge, MA, USA, (Magenta) (NASDAQ: MGTA) associated with the initiation of the GLP toxicology study for the development candidate MGTA-117.
  • Prof. Andreas Pahl, CSO of Heidelberg Pharma AG, commented: "We are delighted that Magenta is advancing the program forward toward clinical trials for MGTA-117.
  • Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies.
  • Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA.

DGAP-News: Heidelberg Pharma Announces Participation at Various Conferences

Retrieved on: 
Thursday, September 10, 2020
Baden, Ladenburg, Rhein-Neckar-Kreis, Heidelberg, Subdivisions of Germany, Geography of Germany, Heidelberg Pharma's proprietary ATAC technology, Heidelberg Pharma

Ladenburg, Germany, 10 September 2020 - Heidelberg Pharma AG (FSE: HPHA) today announced that they will participate at the following events.

Key Points: 
  • Ladenburg, Germany, 10 September 2020 - Heidelberg Pharma AG (FSE: HPHA) today announced that they will participate at the following events.
  • Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany.
  • Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies.
  • Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA.

DGAP-News: Heidelberg Pharma to Present at the Upcoming Virtual European Biotech Investor Day 2020

Retrieved on: 
Wednesday, June 24, 2020
Medicine, Clinical medicine, Immunology, Monoclonal antibodies, Antineoplastic drugs, alpha-Amanitin, Heidelberg Pharma's proprietary ATAC technology, Heidelberg Pharma

Ladenburg, Germany, 24 June 2020 - Heidelberg Pharma AG (FSE: HPHA) today announced that Prof Andreas Pahl, Chief Scientific Officer, plans to present an overview of the company at the upcoming Virtual European Biotech Investor Day 2020 , taking place on 25th June 2020 and hosted by Solebury Trout, Goodwin, Deutsche Bank and Nasdaq.

Key Points: 
  • Ladenburg, Germany, 24 June 2020 - Heidelberg Pharma AG (FSE: HPHA) today announced that Prof Andreas Pahl, Chief Scientific Officer, plans to present an overview of the company at the upcoming Virtual European Biotech Investor Day 2020 , taking place on 25th June 2020 and hosted by Solebury Trout, Goodwin, Deutsche Bank and Nasdaq.
  • Antibody Drug Conjugates (ADCs) combine the high affinity and specificity of antibodies with the potency of cytotoxic small molecules for the treatment of cancer.
  • Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies.
  • Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA.